1-8 of 8
Harald Holte
Close
Sort by
Journal Articles

Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma

Ivana Spasevska, Ankush Sharma, Chloé B. Steen, Sarah E. Josefsson, Yngvild N. Blaker, Arne Kolstad, Even H. Rustad, Saskia Meyer, Kathrine Isaksen, Stalin Chellappa, Kushi Kushekhar, Klaus Beiske, Mette S. Førsund, Signe Spetalen, Harald Holte, Bjørn Østenstad, Marianne Brodtkorb, Eva Kimby, Johanna Olweus, Kjetil Taskén, Aaron M. Newman, Susanne Lorenz, Erlend B. Smeland, Ash A. Alizadeh, Kanutte Huse, June H. Myklebust
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7216–7230.
https://doi.org/10.1182/bloodadvances.2023010158
Published: 2023
Includes: Supplemental data
Journal Articles

A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL

Clinical Trials & Observations
Kathrine T. Isaksen, Maria Adele Mastroianni, Marit Rinde, Leiv Sindre Rusten, Dlawer Abdulla Barzenje, Lloyd Frode Ramslien, Marit Slaaen, Marianne Brenn Jerm, Erlend B. Smeland, Siri Rostoft, Knut Liestøl, Marianne Brodtkorb, Harald Holte
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4771–4782.
https://doi.org/10.1182/bloodadvances.2021004777
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4091–4101.
https://doi.org/10.1182/bloodadvances.2020002583
Published: 2020
Includes: Supplemental data
Journal Articles

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Clinical Trials & Observations
Sirpa Leppä, Judit Jørgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-Merete Fagerli, Thomas Stauffer Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Björkholm, Øystein Fluge, Sirkku Jyrkkiö, Knut Liestøl, Elisabeth Ralfkiaer, Signe Spetalen, Klaus Beiske, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1906–1915.
https://doi.org/10.1182/bloodadvances.2020001518
Published: 2020
Includes: Supplemental data
Journal Articles

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series

Jillian F. Wise, Sigve Nakken, Chloé B. Steen, Daniel Vodák, Gunhild Trøen, Bjarne Johannessen, Ole Christian Lingjærde, Vera Hilden, Yngvild Nuvin Blaker, Baoyan Bai, Lars Birger Aasheim, Annika Pasanen, Susanne Lorenz, Anita Sveen, Ragnhild A. Lothe, Ola Myklebost, Sirpa Leppä, Leonardo A. Meza-Zepeda, Klaus Beiske, Michael S. Lawrence, Eivind Hovig, June Helen Myklebust, Erlend B. Smeland, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1859–1866.
https://doi.org/10.1182/bloodadvances.2019001325
Published: 2020
Includes: Supplemental data
Journal Articles

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Richard T. Maziarz, Edmund K. Waller, Ulrich Jaeger, Isabelle Fleury, Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J. Schuster, Michael R. Bishop, Jason R. Westin, Stephan Mielke, Takanori Teshima, Veronika Bachanova, Stephen R. Foley, Peter Borchmann, Gilles A. Salles, Jie Zhang, Ranjan Tiwari, Lida B. Pacaud, Qiufei Ma, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2020) 4 (4): 629–637.
https://doi.org/10.1182/bloodadvances.2019001026
Published: 2020
Includes: Supplemental data
Journal Articles

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Clinical Trials & Observations
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2230–2236.
https://doi.org/10.1182/bloodadvances.2019000151
Published: 2019
Journal Articles

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

Hakan Köksal, Pierre Dillard, Sarah E. Josefsson, Solrun Melkorka Maggadottir, Sylvie Pollmann, Anne Fåne, Yngvild Nuvin Blaker, Klaus Beiske, Kanutte Huse, Arne Kolstad, Harald Holte, Gunnar Kvalheim, Erlend B. Smeland, June H. Myklebust, Else Marit Inderberg, Sébastien Wälchli
Journal: Blood Advances
Blood Adv (2019) 3 (8): 1230–1243.
https://doi.org/10.1182/bloodadvances.2018029678
Published: 2019
Includes: Supplemental data